- Defence Therapeutics has announced an agreement with the Lady Davis Institute cell processing center in Montreal
- The agreement positions Defence’s AccumTM DC cancer vaccine candidate AccuVAC-D001 to be manufactured with a focus on melanoma and breast cancer
- The agreement will establish the blueprints for the manufacturing process prior to treating melanoma and breast cancer patients
- Defence Therapeutics is a biotechnology company working on engineering the next generation of vaccines and ADC products using its proprietary platform
- Defence Therapeutics Inc. (DTC) opened trading at C$5.70 per share
Defence Therapeutics (DTC) has announced an agreement with the Lady Davis Institute cell processing center (CPC) at the Jewish General Hospital in Montreal.
The agreement positions Defence’s AccumTM DC cancer vaccine candidate AccuVAC-D001 to be manufactured with a focus on melanoma and breast cancer.
The mandate of the Jewish General Hospital CPC is to support early phase clinical trials of cell-based therapies by processing human cells and tissue to treat human illnesses such as cancer. The close proximity of this facility to hospital patients further simplifies the logistics of the trial.
The facility comprises the Clean Room area where cell processing takes place, as well as the Laboratory Annex supporting the Clean Room. It is operated by highly qualified personnel led by Dr. Nicoletta Eliopoulos, a pioneer in cell therapy with a track record of successful implementation and prosecution of custom autologous cellular pharmaceuticals.
“We are a step closer to initiating our Phase I trial using our proprietary AccumTM DC technology with the establishment of this agreement. These studies will not only establish the “blueprints” of our manufacturing process, but they will implement important quality control steps required by regulatory agencies prior to treating melanoma and breast cancer patients,” says Mr. Plouffe, CEO of Defence Therapeutics.
Defence Therapeutics is a biotechnology company focused on engineering the next-generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells.
Defence Therapeutics Inc. (DTC) opened trading at C$5.70 per share.
